Review
Published · Updated · 1 min read
Tarlatamab improved survival in second-line treatment of small cell lung cancer
What it means for practice
New approaches to small cell lung cancer require validation in larger trials. Concurrent thoracic radiotherapy with first-line chemoimmunotherapy increased toxicity without a survival benefit.
Summary
This review covers new therapeutic strategies for small cell lung cancer presented at the 2026 American Society of Clinical Oncology conference. The supplied abstract addresses drug treatments and radiotherapy approaches across different treatment lines.
Drug treatments
Second-line tarlatamab improved intracranial control and overall survival compared with chemotherapy. Ivonescimab combined with liposomal irinotecan, as well as the antibody–drug conjugate ABBV-706, showed promising results in heavily pretreated patients.
Radiotherapy approaches and limitations
The feasibility of targeted internal radiotherapy with 177Lu-SSO110 was demonstrated. However, concurrent thoracic radiotherapy with first-line chemoimmunotherapy increased toxicity without improving survival. These findings concern different therapeutic approaches rather than a direct comparison of all the treatments listed.
The authors’ conclusion points to a broader range of potential treatment options but emphasises the need to validate the findings in larger trials. The abstract provides no sample sizes, quantitative effect estimates, follow-up duration or detailed toxicity findings, limiting assessment of the clinical significance of the reported results.
Source
-
Diversification des approches thérapeutiques dans les CBPC.
Reviewed by: DrugCard editorial team ·
This article does not replace clinical judgement. Disclaimer